Cwa Asset Management Group, LLC Apellis Pharmaceuticals, Inc. Transaction History

Cwa Asset Management Group, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$37.14 - $64.82 $127,204 - $222,008	3,425 New	3,425 $205,000
Q1 2023 Apr 17, 2023	BUY	$46.59 - $66.96 $158,406 - $227,663	3,400 New	3,400 $224,000
Q3 2022 Nov 09, 2022	SELL	$44.76 - $69.66 $44,760 - $69,660	-1,000 Reduced 20.0%	4,000 $273,000
Q2 2022 Jul 21, 2022	BUY	$35.07 - $59.21 $175,350 - $296,050	5,000 New	5,000 $226,000
Q1 2021 May 17, 2021	SELL	$40.8 - $57.39 $163,200 - $229,560	-4,000 Closed	0 $0
Q4 2020 Feb 09, 2021	BUY	$30.79 - $57.2 $123,160 - $228,800	4,000 New	4,000 $229,000

301

111M

2.63M

845K

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.67B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Cwa Asset Management Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Cwa Asset Management Group, LLC with notifications on news.